阿托伐他汀早期应用对急性心肌梗死患者血清PⅢNP、MMP-9、hs-CRP水平的影响  

Effects of atorvastatin therapy on serum PⅢNP,MMP-9 and hs-CRP levels of patients with acute myocardial infarction

作　　者：康海[1] 杨军[1] 方毅民[1] 任法新[1] 林绍霞[1] 

机构地区：[1]青岛大学医学院附属烟台毓璜顶医院,山东烟台264000

出　　处：《山东医药》2008年第7期1-3,共3页Shandong Medical Journal

基　　金：烟台市科技发展计划项目(2006131-4)

摘　　要：目的研究早期应用阿托伐他汀对急性心肌梗死(AMI)患者稳定斑块、减少炎症反应、减少胶原沉积的作用。方法采用随机、对照的方法将入选并完成随访的91例AMI患者分为大剂量组、常规剂量组和对照组。对照组接受常规治疗,大剂量组和常规剂量组分别在常规治疗的基础上口服阿托伐他汀40 mg/d和10 mg/d,连续用药12周。比较AMI后24 h内和第12周末患者血清Ⅲ型前胶原氨基末端肽(PⅢNP)、基质金属蛋白酶9(MMP-9)、高敏C反应蛋白(hs-CRP)的水平。结果阿托伐他汀大剂量组和常规剂量组治疗12周时血清PⅢNP、MMP-9、hs-CRP水平均显著低于对照组,大剂量组各项指标的水平亦显著低于常规剂量组。结论早期应用阿托伐他汀治疗可减轻AMI患者冠状动脉粥样斑块的炎症反应,减少Ⅲ型胶原沉积,从而稳定斑块、改善胶原重塑。Objective To observe the influence of atorvastatin on serum PⅢNP, MMP-9 and hs-CRP levels of patients with acute myocardial infarction（AMI）. Methods 91 patients with first acute ST segment elevation myocardial infarction were randomized to control group, conventional-dose atorvastatin group（ 10 mg/day, for 12 weeks） and high-dose atorvastatin groups （40 mg/day, for 12 weeks） respectively. The serum levels of PⅢNP, MMP-9 and hs-CRP were measured in 24 hours after AMI and 12 weeks later,respectlvely. Results 12 weeks later, the levels of hs-CRP,MMP-9 and PⅢNP in high-dose atorvastatin group were significantly lower than those both in conventional-dose atorvastatin group and in the control group, whereas the levels of hs-CRP、MMP-9 and PⅢNP in conventional-dose atorvastatin group were also lower than those in the control group significantly. Conclusions Atorvastatin may decrease the breakdown of matrix collagen, decreased collagen type Ⅲ and reduced inflammatory react/on in the patients with AMI.

关 键 词：阿托伐他汀 心肌梗死 急性 前胶原氨基末端肽 Ⅲ型 基质金属蛋白酶9 C反应蛋白 高敏 

分 类 号：R541.4[医药卫生—心血管疾病]